CLINICAL TRIALS PROFILE FOR VIIBRYD

All Clinical Trials for VIIBRYD

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01473381 ↗	Safety and Efficacy of Vilazodone in Major Depressive Disorder	Completed	Forest Laboratories	Phase 4	2011-12-01	The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder.
NCT01473394 ↗	Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder	Completed	Forest Laboratories	Phase 4	2011-12-01	The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder.
NCT01573598 ↗	Safety and Efficacy of Vilazodone in Major Depressive Disorder	Completed	Forest Laboratories	Phase 4	2012-04-01	Safety and Efficacy of Vilazodone in Major Depressive Disorder
NCT01574183 ↗	Vilazodone Treatment for Marijuana Dependence	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	2012-08-01	Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of vilazodone for reducing marijuana use in marijuana-dependent adults. A contingency management intervention (CM)and motivational enhancement therapy (MET)will be incorporated to encourage study engagement and retention, and genomic DNA will be extracted to characterize subjects according to polymorphisms of genes potentially relevant to the activity of vilazodone. It is hypothesized that vilazodone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.
NCT01574183 ↗	Vilazodone Treatment for Marijuana Dependence	Completed	Medical University of South Carolina	Phase 2	2012-08-01	Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of vilazodone for reducing marijuana use in marijuana-dependent adults. A contingency management intervention (CM)and motivational enhancement therapy (MET)will be incorporated to encourage study engagement and retention, and genomic DNA will be extracted to characterize subjects according to polymorphisms of genes potentially relevant to the activity of vilazodone. It is hypothesized that vilazodone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.
NCT01608295 ↗	Vilazodone for Treatment of Geriatric Depression	Completed	Forest Laboratories	Phase 4	2012-07-01	The purpose of this study is to examine the effects of vilazodone for the treatment of depression in older adults.
NCT01608295 ↗	Vilazodone for Treatment of Geriatric Depression	Completed	University of California, Los Angeles	Phase 4	2012-07-01	The purpose of this study is to examine the effects of vilazodone for the treatment of depression in older adults.

Clinical Trial Conditions for VIIBRYD

Condition Name

Condition Name for VIIBRYD
Intervention	Trials
Major Depressive Disorder	9
Comorbidity	1
Healthy	1
Hot Flushes	1

Condition MeSH

Condition MeSH for VIIBRYD
Intervention	Trials
Depression	10
Depressive Disorder, Major	10
Depressive Disorder	10
Disease	8

Clinical Trial Locations for VIIBRYD

Trials by Country

Trials by Country for VIIBRYD
Location	Trials
United States	134
Ukraine	5
Serbia	4
Canada	4
Germany	3

Trials by US State

Trials by US State for VIIBRYD
Location	Trials
Texas	7
New York	7
Florida	7
California	7
Virginia	6

Clinical Trial Progress for VIIBRYD

Clinical Trial Phase

Clinical Trial Phase for VIIBRYD
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	4
Phase 2	2

Clinical Trial Status

Clinical Trial Status for VIIBRYD
Clinical Trial Phase	Trials
Completed	13
Terminated	1
Unknown status	1

Clinical Trial Sponsors for VIIBRYD

Sponsor Name

Sponsor Name for VIIBRYD
Sponsor	Trials
Forest Laboratories	13
National Institute on Drug Abuse (NIDA)	1
Medical University of South Carolina	1

Sponsor Type

Sponsor Type for VIIBRYD
Sponsor	Trials
Industry	13
Other	9
NIH	1

Last updated: May 1, 2026

Viibryd (vilazodone): Clinical Trials Update, Market Analysis, and Projection

What is Viibryd (vilazodone) and what is its current market position?

Viibryd is vilazodone, an oral antidepressant marketed in the US by Allergan (AbbVie) and originally developed for major depressive disorder (MDD). Its commercial footprint is defined by (1) limited patent-driven differentiation versus broader generic antidepressant competition and (2) comparatively narrow pull versus dominant brands in the modern MDD market (SSRIs, SNRIs, and pipeline-led new mechanisms).

Key market-relevant facts

• Indication (core label): Major Depressive Disorder (MDD) in adults.
• Regulatory status: Marketed in the US; long-established launch means commercial performance is constrained more by competitive positioning than by active exclusivity cycles.
• Competition profile: Persistent pressure from generics and from newer branded options (within class and cross-mechanism) that have stronger modern prescribing momentum.

Demand drivers that matter for projection

• Share of prescriptions shifts driven by payer formularies and step therapy.
• Net price and rebate compression typical for mature branded CNS assets.
• Safety/tolerability perceptions in real-world practice relative to SSRIs/SNRIs and other branded CNS MDD options.

What is the clinical trials update for vilazodone (Viibryd)?

A complete, current “clinical trials update” requires a live trial registry view (e.g., ClinicalTrials.gov status for ongoing studies, recruiting/active-not-recruiting pipelines, and results postings). The necessary trial-state data is not present in the provided context, and producing a fabricated update would be inaccurate.

Clinical-trial readout constraints

• No registry-linked, date-stamped trial status inputs are provided.
• No protocol identifiers (NCT numbers) or specific study phases are provided.
• No results postings or withdrawal/termination decisions are provided.

Result: A factual clinical-trials update for Viibryd cannot be produced from the information available in this request without risking incorrect statements.

What do the historical clinical packages imply about future uptake?

Even without an updated trial registry feed, the clinical package implications for market modeling are clear for a mature, established antidepressant:

Practice-relevant attributes

• Oral once-daily therapy supports adherence versus more complex regimens.
• Tolerability profile and discontinuation experience drive switching decisions.
• In a mature MDD market, differentiated clinical outcomes must translate into measurable formulary and prescribing wins to offset generic erosion.

Implication for projection

• Without evidence of a new pivotal program that refreshes exclusivity or expands label meaningfully, vilazodone’s long-run trajectory typically follows a mature branded CNS pattern: declining or plateauing volume with price and contracting dynamics.

Market analysis: how Viibryd is likely to perform under generic and payer pressure

To project a mature MDD brand, the model centers on net revenue mechanics rather than pipeline optimism:

Market structure

• MDD prescribing is commoditizing: long-running classes (SSRIs/SNRIs) dominate baseline prescribing, with generic substitution limiting branded share.
• Payers enforce step therapy: branded CNS must compete on formulary placement and PA criteria.
• Switching is sticky but not reversible fast: if a patient stabilizes, they may stay, but new patient starts often go to preferred agents.

Viibryd-specific commercialization constraints

• Generic penetration and class competition reduce incremental patient starts.
• Any sustained revenue requires at least one of:
  • formulary resilience (preferred access),
  • payer-contract stability and net price maintenance,
  • durable share from patient tolerability preference.

Projection: likely revenue and lifecycle pattern

A projection requires baseline revenue, unit volume, channel mix, and payer/net-price assumptions. None are provided here, and providing numeric projections would require inventing an input set.

Result: A factual market projection for Viibryd cannot be computed from the information available in this request.

Actionable business implications for R&D and investment

What should stakeholders infer about the investment case for vilazodone?

• For an established branded antidepressant, returns are mostly driven by net price retention and formulary positioning, not by marginal clinical differentiation alone.
• Investment logic tends to favor programs with new exclusivity events (new indication, new formulation with distinct patent coverage, or demonstrably differentiated efficacy in a new patient subgroup).

What should R&D teams do with Viibryd as a benchmark?

• Use vilazodone’s historical profile as a benchmark for:
  • endpoint selection in MDD trials,
  • tolerability messaging strategy,
  • differentiation frameworks that resonate with payers and prescribers.

Key Takeaways

• Viibryd (vilazodone) is a mature, branded MDD asset subject to ongoing generic and payer-driven erosion dynamics.
• A factual, date-stamped clinical trials update cannot be produced from the information provided in this request.
• A numeric market projection cannot be produced without revenue/volume/net-price baseline inputs.
• Business outcomes for mature CNS brands typically hinge on formulary resilience, net pricing, and patient-stability effects rather than pipeline-led growth.

FAQs

1. Is Viibryd still prescribed for major depressive disorder in adults?
   Yes. It remains a marketed treatment for MDD in adults.

2. Does Viibryd have ongoing clinical trials that could change its label?
   A registry-based update cannot be generated from the provided information.

3. What drives Viibryd performance versus newer MDD brands?
   Formulary access, payer contracting, and patient retention typically dominate in mature branded CNS products.

4. How does generic competition affect vilazodone’s market outlook?
   It generally suppresses incremental patient starts and pushes the market toward net-price compression.

5. What types of R&D moves would most change Viibryd’s long-term outlook?
   New exclusivity events such as expanded indications with supportive pivotal data, or patent-refreshing formulation strategies with clear clinical or practical advantages.

References

[1] Viibryd (vilazodone) prescribing information. FDA.
[2] ClinicalTrials.gov. Vilazodone (search results and trial status pages).